Don't miss an issue! Renew/subscribe for FREE today.

C3 Jian Completes Phase 1 Clinical Study Enrollment for Novel Peptide Therapeutic

Posted on Wednesday, October 9, 2013


LOS ANGELES, Feb. 19, 2013 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced the successful completion of Phase 1 study enrollment for its novel peptide therapeutic, C16G2.

C16G2 is a synthetic peptide derived from C3 Jian's proprietary, pheromone signaling platform technology referred to as STAMPS (Specifically Targeted Antimicrobial Peptides). C16G2 has demonstrated activity selectively targeting Streptococcus mutans, a cavity-causing organism. The current indication sought for C16G2 is prevention of dental caries in adults, adolescents and pediatrics. Dental caries, commonly known as tooth decay or a cavity, is rated the most common chronic childhood disease according to the U.S. Surgeon General. In the U.S. alone, over $100 billion is spent annually on oral health expenditures. A majority of these expenses is directly related to dental caries.

"Completion of enrollment for the Phase 1 trial is a significant achievement for C3 Jian and expected to provide clinical information contributing to the ongoing and dynamic development program for C16G2," said Laura A. Navalta, C3 Jian's Vice President of Clinical Operations.  

The double-blind Phase 1 clinical trial included a dose escalation period and focused on evaluating the safety, pharmacokinetics and microbiology of C16G2 administered in a single oral dose in mouth rinse to healthy adult subjects. This study was conducted at New York University, Bluestone Center for Clinical Research. Mark Wolff, DDS, PhD, Professor and Chair of the Department of Cariology & Comprehensive Care at NYU College of Dentistry, served as the Principal Investigator of the study. This study is C3 Jian's first Phase 1 clinical trial.  

"Our collaboration with Dr. Wolff and Bluestone has resulted in a quality run program and we are pleased with the progress of our first clinical trial. Over the next several months we will obtain and assess the data that will help us map the future advancement of C16G2. With appropriate results, it is our hope to begin Phase 2 studies in 2014," said Todd R. Patrick, C3 Jian's President and CEO.

Recent Headlines

© 2024 BroadcastMed LLC | Privacy Policy